Redeye provides an update following Neola Medical’s Q2 2026 report. We argue that the report was relatively undramatic and broadly in line with our expectations. We are positive that the company has now secured funding and see no near-term need for additional capital. In this update, we have only made minor fine-tuning adjustments to our estimates. We also introduce our new fair value, which suggests that the share is currently attractively priced.
LÄS MER
